Onyx Biotec share price
NSE: ONYXPharmaceuticals & Biotechnology
Last close ₹37.00₹0.00 (0.00%)
Share price at the NSE close on 23 Oct 2026. Previous close ₹37.00.
52-week range of traded prices to 23 Oct 2026
₹24.20Low, 22 May 2026₹49.65High, 5 Aug 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price.
- ₹67 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 14 May 2026
- 1.2
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 14 May 2026
- −0.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 14 May 2026
- 0.27
- Volume, NSEVolume. Shares traded on the last trading day.
- 4,000
Results
Standalone; ₹ crore, the charts by years to March, the table by half year.Half-yearly results
Half year to Mar 2026, against the half year beforeFiled 14 May
- RevenueRevenue. The pill is the change in revenue against the half year before: this period's figure divided by that one's, less one, in per cent.
- ₹35 Crup 0.87%
- Net profitNet profit. Under it, net profit in the half year before. A change in per cent is not worked out where either period is a loss or nothing.
- ₹0.69 CrHalf year to Sep 2025: −₹0.90 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 2.0%
Revenue by year
Peak revenue ₹69 Cr, year to Mar 2026
Net profit by year, a loss in red
- Net profit
- Loss
A loss in the year to Mar 2026, −₹0.21 Cr
| ₹ crore | Sep 2024 | Mar 2025Filed 28 May | Sep 2025Filed 13 Nov | Mar 2026Filed 14 May |
|---|---|---|---|---|
| Revenue | 30.1 | 31.8 | 34.6 | 34.9 |
| Net profit | 3.0 | 2.0 | −0.9 | 0.7 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 9.9% | 6.2% | −2.6% | 2.0% |
Standalone. The 4 half years from Sep 2024, the first on record. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, manufacture and sale distribution of generic and proprietary pharmaceutical products, which carries all its revenue.
Valuation
Today, against the company's own history. Not shown, P/E: loss, last twelve months. Not shown, EV/EBITDA: a period of the last twelve months does not state its operating profit. Dividend yield is not shown: no dividend in the years on record.PE ratio and valuation history
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 45% of 220 trading days over the last year.
LowestHighest
Its median1.2Industry median2.9
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −41.4% | – | – | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record. Earnings growth over 1 year is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Onyx Biotec in market cap.
Onyx Biotec is not on the chart: it has no P/E today
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Sunil HealthcareSUNLOC | 71 | 19.9 | 1.0 | 10.0 | −0.6% | +1,851.4% | 5.2% | 4.9% | 0.00% |
 Source Natural Foods & Herbal SupplSOURCENTRL | 70 | 18.6 | 2.7 | 11.9 | +63.1% | +20.6% | 15.6% | 16.7% | 0.00% |
 Vineet LaboratoriesVINEETLAB | 70 | – | – | – | – | – | – | – | 0.00% |
 Zenith DrugsZENITHDRUG | 68 | 17.2 | 0.9 | – | +28.4% | −44.9% | 5.5% | – | 0.00% |
 PhaarmasiaPHRMASI | 62 | 3.5 | 2.8 | 28.6 | +111.8% | – | 114.5% | 7.1% | 0.00% |
 Rekvina LaboratoriesVINRKLB | 62 | – | – | – | – | – | – | −139.0% | 0.00% |
 Vivimed LabsVIVIMEDLAB | 50 | – | – | – | – | – | – | – | 0.00% |
 Biofil Chemicals & PharmaceuticalsBIOFILCHEM | 47 | 97.0 | 2.2 | 59.5 | +9.3% | −82.7% | 2.4% | 2.1% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
7 Oct · Updates
Sep 2026
Onyx Biotec share price by year
Each calendar year to 2025.Onyx Biotec share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 40.80 | −54.5% | 94.85 | 30.80 |
| 2024 | 89.60 | – | 89.60 | 53.35 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2024 is from its first session, 22 Nov 2024.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 37.00 | 37.00 | 37.00 | 37.00 | 37.00 | 4,000 | – |
| 22 Oct 2026 | 38.85 | 38.85 | 37.00 | 37.00 | 37.37 | 10,000 | 100.0% |
| 21 Oct 2026 | 37.25 | 37.25 | 37.00 | 37.00 | 37.12 | 4,000 | 100.0% |
| 19 Oct 2026 | 37.25 | 37.25 | 37.25 | 37.25 | 37.25 | 2,000 | 100.0% |
| 16 Oct 2026 | 37.25 | 37.25 | 37.25 | 37.25 | 37.25 | 2,000 | 100.0% |
| 15 Oct 2026 | 38.00 | 39.00 | 37.05 | 37.05 | 38.35 | 24,000 | 100.0% |
| 14 Oct 2026 | 37.50 | 37.50 | 37.50 | 37.50 | 37.50 | 2,000 | 100.0% |
| 13 Oct 2026 | 37.00 | 37.00 | 37.00 | 37.00 | 37.00 | 4,000 | 100.0% |
| 9 Oct 2026 | 37.55 | 39.40 | 37.55 | 38.00 | 38.48 | 32,000 | 93.8% |
| 8 Oct 2026 | 39.45 | 39.45 | 37.55 | 37.55 | 38.23 | 12,000 | – |
Prices in ₹ per share as traded, not adjusted.
Company details
- Legal name
- Onyx Biotec Limited
- NSE symbol
- ONYX
- ISIN
- INE0WVU01018
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Nov 2024
- Face value
- ₹10